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Mutation in blood coagulation
factor V associated with
resistance to activated
protein C
cofactor II came from linkage studies in a large family with APC
resistance (Fig. 2α). The human locus for the factor V gene (F5)
has been mapped to chromosome l (lq21-25)12. There are no
reports of polymorphic F5 markers13"17 that can be amplified
by polymerase chain reaction (PCR). Therefore, we tested the
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ACTIVATED protein C (APC) is a serine protease with potent anti-
coagulant properties, which is formet! in blood on the endothelium
from an inactive precursor1. During normal haemostasis, APC
limits clot formation by proteolytic inactivation of factors Va and
Villa (ref. 2). To do this efficiently the enzyme needs a non-
enzymatic cofactor, protein S (ref. 3). Recently it was found that
the anticoagulant response to APC (APC resistance)4 was very
weak in the plasma of 21% of unselected consecutive patients with
thrombosis5 and about 50% of selected patients with a personal or
family history of thrombosis6'7; moreover, 5% of healthy indi-
viduals show APC resistance, which is associated with a sevenfold
increase in the risk for deep vein thrombosis5. Here we demonstrate
that the phenotype of APC resistance is associated with hetero-
zygosity or homozygosity for a single point mutation in the factor
V gene (at nucleotide position 1,691, G -»A Substitution) which
predicts the synthesis of a factor V molecule (FV Q506, or FV
Leiden) that is not properly inactivated by APC. The allelic fre-
quency of the mutation in the Dutch population is ~2% and is at
least tenfold higher than that of all other known genetic risk
factors for thrombosis (protein C (ref. 8), protein S (ref. 9),
antithrombin10 deficiency) together.
The responsiveness of plasma to APC is measured äs the ratio
of two activated partial thromboplastin times, one in the pres-
ence of APC and one in its absence4'5'7. This APC-sensitivity
ratio (APC-SR) is normalized to the ratio obtained with a refer-
ence plasma (n-APC-SR). Resistance to APC is defined by
a n-APC-SR < 0.84 (1.96 s.d. below the mean n-APC-SR in 100
healthy controls, after outlier removal).
Analysis of the parentships of 14 unrelated APC-resistant
patients led to the concept of a familial form of APC resistance
(or deficiency of APC cofactor II4) in which homozygotes and
heterozygotes can be identified on the basis of the n-APC-SR
(Fig. l legend). Further support for this came from mixing equal
volumes of normal plasma and plasma from a patient classified
äs homozygous cofactor II-deficient (n-APC-SR, 0.38), which
gave a n-APC-SR of 0.57 (Fig. Ια). This is identical to the ratio
for plasma from patients heterozygous for the deficiency (mean
n-APC-SR, 0.58). Mixing the plasma of four unrelated homo-
zygous APC cofactor II-deficient patients (mean n-APC-SR,
0.40) did not alter the ratio, indicating that in all four patients
the same plasma protein was missing or defective (see also refs
4 and 7).
To investigate whether APC cofactor II activity is a feature
of one of the known blood coagulation proteins, APC cofactor
II was assayed in a series of plasmas deficient in a single protein
(Fig. I b ) . All contained normal levels of APC cofactor II (60-
155%) apart from plasma deficient in factor V (<5%). Addition
of isolated human factor V to factor V-deficient plasma intro-
duced factor V coagulant activity and APC cofactor II activity,
suggesting that the latter is related to factor V (see also ref. 11).
Independent support for the identity of factor V with APC
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FIG. l Measurement of APC-cofactor II levels in plasma. a, Calibration
curve for the assay of APC-cofactor II activity in plasma. APC cofactor
II refers to the hypothetical new cofactor of APC4 which is missing or
defective in individuals with APC resistance. n-APC-SRs were measured
in dilutions of normal plasma (100% APC cofactor II) in plasma of a
patient homozygous-deficient in APC cofactor II (0% APC cofactor II).
The curve in a is the result of nine different experiments. The classifica-
tion äs homozygous- or heterozygous-deficient in APC cofactor II is
based on the results of parentship analysis for 14 probands with APC
resistance (n-APC-SR <0.84). For 2 probands (n-APC-SR, 0.38/0.41),
both parents were APC resistant (mean n-APC-SR 0.55); for 11 probands
(mean n-APC-SR 0.57) one of the parents was APC resistant (mean n-
APC-SR 0.59) whereas the other was not (mean n-APC-SR 0.96); for
one proband (n-APC-SR 0.74), neither parent was affected (n-APC-SR
0.96/0.99). We propose that individuals can be classified äs homozyg-
otes or heterozygotes for APC cofactor II deficiency on the basis of their
n-APC-SR (homozygotes: mean 0.40, n = 2; heterozygotes: mean 0.58,
ränge 0.51-0.67, n = 26). o, APC cofactor II activity levels in plasmas
deficient (<5%) in a single coagulation factor. Plasmas were either from
patients with a congenital deficiency (a, g, f, m, g, r, s, t) or prepared
by immunodepletion (b, c, d, e, j, h, i, k, l, p). Plasmas were deficient in
factor II (a), factor VII (b), factor IX (c), factor X (d), factor XI (e), factor
XII (j), factor XIII (g), protein C (l), protein S (i), ß2-glycoprotein (j),
antithrombin (k), factor V (l, m), factor VIII (p, q) or von Willebrand factor
(r, s, t). Factor V-deficient plasma (m) was supplemented with two
different concentrations, 54% (n) and 90% ίο), of purified human factor
V (Serbio, Gennevilliers, France), dialysed against 20 mM sodium citr-
ate, 150 mM NaCI, 4 mM CaCI2 and tested for APC cofactor II activity.
METHODS. The APC-SR was calculated from the results of two activated
partial thromboplastin times, one measured in the presence of APC and
one in its absence, äs before5. The n-APC-SR was calculated by dividing
the APC-SR for the test sample by the APC-SR for pooled normal plasma.
APC cofactor II activity was measured by reading the n-APC-SR for two
different dilutions (1:1, 3:4) of the test plasma in APC cofactor II-
deficient plasma on a calibration curve äs shown in a.
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segregation of microsatellite markers for several loci in the Iq21-
25 region (Fig. 1b) in the family. Significantly positive results
were obtained only for locus D1S61 (Zmax 7.27 at 0 = 0.00),
which is located within 4 cM of the F5 locus (see table in Fig.
2c).
We then searched for an associated mutation(s) in the factor
V gene in regions containing the putative APC-bmding site (cor-
responding to ammo-acid residues 1,865-1,874)1819 and the
putative APC cleavage site (Arg 506)l3"20. Ectopic transcripts of
the factor V gene from blood lymphocytes were used for first-
strand synthesis of complementary DNA and subsequent amph-
fication of the two regions codmg for the APC bmding and
cleavage sites. Direct sequencing of the PCR fragments revealed
that two patients, classified äs homozygous for deficiency of
APC cofactor II, were both homozygous for a guanine to aden-
me Substitution at nucleotide 1,691 (1,691G->A) (Fig. 3ö). This
mutation predicts the replacement of Arg 506 (CGA) by Gin
(CAA) (FV Q506 or FV Leiden). No other sequence abnormali-
ties were detected in 225 base pairs (bp) incorporating 1,691 A
or in 275 bp around the region coding for the putative APC-
binding site (Fig. 36).
If cleavage after Arg 506 is necessary for inactivation of
human factor Va by APC, mtroduction of a glutamme at posi-
tion 506 should prevent inactivation. During coagulation, factor
V is first activated by factor Xa (with formation of a 105/220K
heterodimer21) and then processed by thrombin (with formation
of a 105/74K heterodimer22'21). We find that replacement of Arg
506 by Gin prevents inactivation by APC of factor Va formed
after addition of factor Xa (Fig. 3c), but not that of factor Va
formed after addition of α-thrombin (data not shown).
As two unrelated APC-resistant patients were homozygous
for the same mutation, this alteration may predominate in other
APC-resistant patients. We therefore designed a lest to scrcen
genomic DNA for the presence of the l ,691G -> A Substitution.
The mutation is located m exon 10, 11 nucleotides 5' of the Start
of intron 10, and äs only the first 8 nucleotides of intron 10
have been sequenced16, we generated more intron 10 sequence
by heminested reverse PCR24 and then designed primers for the
amplification of two overlapping genomic fragments for use in
genotypmg.
The 267-bp fragment was digested with Mnll to establish
whether the allele was normal (G at 1,691) or mutated, and
hybridization of the 222-bp fragment with oligonucleotides
specific for each allele was used to confirm the presence of aden-
ine at nucleotide 1,691. Using this approach, we investigated all
the members of the pedigree shown in Fig. 2α. There was com-
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FIG 2 Lmkage analysis in a family with APC-resistance. a, Pedigree of
a family with APC-resistance (or APC cofactor II deficiency). This pedigree
forms part of a larger pedigree origmally identified in our laboratory
because of symptomatic type-l protem C deficiency. ·, ·, Individuais
with n-APC-SR<0.84 (mean 0.65; ränge 0.59-0.71, n = 13); O, D,
mdividuals with n-APC-SRC>0.84 (mean 1.03; ränge 0.87-1.29; n =
20); ®, ü, patients treated with oral anticoagulants (measurement of
n-APC-SR m these patients is not meanmgful), O, Q, mdividuals not
tested. History of venous thrombosis. II 3, 6, 8 and 14, and III l, 9, 20
and 22; carriers of the protem C mutation (residue at position 230,
R -> C): II 3, 6, 8 and 14; III l, 5, 7, 9, 12, 18, 20, 22 and 23 and IV
l, 3, 4, 10 and 12. b, Integrated genetic Imkage map of the q21-25
region of chromosome 1. The relative positions of the loci APOA2,
D1S104, D1S61, AT3, LAMB and F13B were derived from the NIH/
CEPH Collaborative Mappmg Group Imkage map25. The genetic distance
between adjacent loci is given m cM. The F5 locus was placed on this
map within 4 cM of the D1S61 locus by studymg the segregation of
markers for the F5 and D1S61 loci m 3 CEPH famihes informative for
both markers (m 55 meioses, no recombination between these two loci
was observed: Zmax 16.6 at 0 = 000). c, Pairwise lodscores of APC-
resistance with chromosome l markers. All available mdividuals of the
pedigree shown m a were analysed. Ohgonucleotide sequences for mar-
kers for the loci ApoA2, D1S104, D1S61, LAMB and F13B are available
from the Genome Data Bank. Primers were obtained from the Dutch
primer base Three different polymorphic markers for the AT3 locus
were not informative m this family Two-point Imkage analysis was per-
formed usmg the MLINK program from the LINKAGE package version
5.3 (from J Ott). Sex-averaged lodscores are shown.
METHODS Microsatellite markers for ApoA2, D1S104, D1S61, LAMB
and F13B were amplified by PCR. Conditions: 50 mM NaCI, 10 mM Tns-
HCI, pH 9.6, 10 mM MgCI2, 0.01% BSA, 200 μΜ dGTP, dATP and dTTP,
20 μΜ dCTP, 0.7 μΟ [a-32P]dCTP, 0.43 U Taq polymerase (Cetus), 50 ng
of each primer and 30 ng genomic DNA 27 Cycles were run at 94 °C
(l mm), 55 °C (2 mm) and 72 °C (l mm), with a final elongation step of
10 mm PCR products were separated on a 6% denaturmg polyacrylam-
ide sequence gel, after which gels were dried and exposed to X-ray film.
F5 polymorphisms: A 636-bp fragment from exon 13 of the factor V
gene16 was amplified by PCR usmg the primers 5'-TGCTGACTATGATT-
ACCAGA-3' (PR-766, nucleotides 2,253-2,272; ref 13) and 5'-GAGT-
AACAGATCACTAGGAG-3' (PR-768, nucleotides 2,870-2,899; ref. 13).
For PCR conditions, see legend to Fig. 4. Restriction with H/nfl detects
a C/T dimorphism at nucleotide 2,298 (C: 0.68; T: 0.32) and a rare
A/G dimorphism at nucleotide 2,411 (A, 0.98; G, 002). None of
these markers was informative in the pedigree m a.
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FIG. 3 Identification of the factor V gene muta-
tion in a patient homozygous-deficient in APC
cofactor II. a, Autoradiogram showingthe nucleo-
tide Substitution in a patient classified äs homo-
zygous-deficient in APC cofactor II. Part of the
nucleotide sequence of the non-coding strand of
a cDNA PCR fragment (coding for amino acids
417-572 in human factor V13) is shown for one
patient (P) and one non-APC-resistant control (C).
Arrows indicate the location of the 1.691G -> A
transition, which predictsthe replacement of Arg
506 by Gin. b, Schematic representation of the
factor V molecule. Human factor V is a 330K
glycoprotein which contains several types of
internal repeats13. Activation by factor Xa results
in the formation of a 105/220K heterodimer
(A1A2/B'A3C1C2)22; activation by thrombin results
in the formation of a 105/74K heterodimer
(AiAj/AadCs)21. APC binds to the A3 domain of
factor Va18·19 and inhibits bovine factor Va by
cleavage in the A2 domain after Arg 505 (ref.
20). The ammo-acid sequences surrounding the
(putative) APC cleavage site in human (Arg 506)
and bovine (Arg 505) factor Va26 are shown. In
the APC-resistant patient, Arg 506 has been
replaced by Gin. c, Resistance of factor Xa-activ-
ated factor V (Q506) to inactivation by APC.
AI(OH)3-adsorbed and fibrinogen-depleted
plasma (for 2 h at 37 °C using 0.3 U ml"1; Arvin) containing either factor
V R506 or factor V Q506 was treated with factor Xa (2 n M) in the
presence of 20 mM CaCI2 and 20 μΜ PS/PC (25/75). After 8 min, when
the factor Va level had reached a plateau, 1.9 nM APC or buffer was
added. At different time intervals, 10 μΐ sample was diluted 1/100 in
'stop' buffer (50 mM Tris-HCI, pH 7.9, 180 mM NaCI, 0.5 mg mr1 OVA,
5 mM CaCI2 and 0.5 ug ml"1 heparin) and directly assayed for factor Va
activity äs described . The factor Va activity measured after complete
activation of 0.70 U mr1 FV (R506) (0.64 μΜ thrombin min"1) or
0.49 U mf1 FV (Q506) (0.20 μΜ thrombin mm"1) is arbitrarily put at
100%; O, no APC; ·, +APC.
METHODS. cDNA synthesis: RNA was isolated28 from the lymphocyte
fraction of 10 ml citrated blood of consenting patients and non-APC-
resistant controls. RNA (l μg) was used äs template for first-strand cDNA
synthesis in the presence of mixed random hexamers using the
A T C Gint
Hum FV SerArgSerLeuAspArgArg GlylleGln
Bov FV SerArgSerLeuAspArgArg GlylleGln
l APC
F V (R506) F V (Q506)
Time (min)
superscript kit (BRL). Amplification of cDNA fragments: the primers 5'-
GCATTTACCCTCATGGAGTG-3' (PR-764, nucleotides (nt) 1,421-1,440;
ref. 13) and 5'-CAAGAGTAGTTATGCTCTCAGGCAC-3' (PR-856, nt 1,867-
1,891; ref. 13) amplify the region coding for residues 417-572 which
contains the putative APC cleavage site; the primers 5'-
CACGTGGTTCACTTTCACGG-3' (PR-849, nt 5,608-5,627; ref. 13) and 5'-
TGTGGTATAGCAGGACTTCAGGTA-3' (PR-848, nt 6,040-6,063; ref. 13)
amplify the region coding for amino-acid residues 1,812-1,963, which
contains the APC-binding region. PCR conditions are described in Fig.
4 legend. PCR fragments were purified on ultra-low-gellingtemperature
agarose and directly sequenced äs before29 using the same primers
äs in the PCR reaction. One additional primer was synthesized to aid
sequencingof the APC-binding region: 5'-TATAAGATCCACCATTGT-3'(PR-
847, nt, 5,905-5,927; ref. 13).
FIG. 4 Association of APC resistance with the presence of
a 1,691A allele of factor V. a, Cosegregatior, of 1.691A with
APC resistance. Upper, position of the individuals in the
pedigree shown in Fig. 2a and their n-APC-SR, if available
(116 was on oral anticoagulant treatment). Middle, Mn/l
digestion of the 267-bp PCR fragment. Lower, dot-blot
hybridization of the 222-bp fragment with the biotinylated
oligonucleotide specific for the 1.691A allele (PR-1005). ö,
Dot-blot hybridization of the 222-bp PCR fragments of 64
thrombosis patients with n-APC-SRC < 0.84 and of their 64
matched controls with the biotinylated oligonucleotide
specific for the 1.691A allele (PR-1005). All patients (P) and
controls (C) gave their informed consent. Slashes denote
positions of failed PCR reactions in this experiment,
METHODS. Amplification of genomic fragments containing
1.691G/A. For Mn/l digestion a 267-bp fragment was
amplified using äs 5' primer 5'-TGCCCAGTGCTTAACAAG-
ACCA-3' (PR-6967; nt 1,581-1,602; ref. 13) and äs 3'
primer 5'-TGTTATCACACTGGTGCTAA-3' (PR-990; nt 127 to
-146 in intron 10). For dot-blot hybridization, a 222-bp
fragment was amplified using äs 5' primer 5'-GAGAGAC-
ATCGCCTCTGGGCTA-3' (PR-6966, nt 1,626-1,647; ref. 13)
and äs 3' primer PR-990. Conditions: 125 μΐ of a mixture
containing 54 mM Tris-HCI, pH 8.8, 5.4 mM MgCI2, 5.4 μΜ
EDTA, 13.3 mM (NH4)2S04, 8% DMSO, 8 mM jö-mercapto-
ethanol, 0.4 mg mr1 BSA, 0.8 mM of each nucleoside tri-
phosphate, 400 ng of each primer, 200-500 ng DNA and
polymerase were subjected to 36 cycles of 91 °C (40 s), 55
and 71 °C (2 min). The 267-bp fragment (7-10 μΐ) was digested with
0.4 U Mn/l (Biolabs): the 1.691G fragment will give fragments of 67, 37
and 163 bp, whereas the 1.691A fragment will give fragments of 67
and 200 bp. The 222-bp fragment (~100 ng) was used for dot-blot
i n"
200-1
163-1
":>Ί· r,
1691-A
2 U Iaq
'C (40 s)
hybridization with biotinylated sequence-specific oligonucleotides (5'-
TGGACAGGCgAGGAATAC-3' (PR-1006; nt 1,682-1,699; ref. 13) for
detection of 1.691G and 5'-TGGACAGGCaAGGAATAC-3' (PR 1005) for
detection of 1.691A. Procedures have been described30. After hybrid-
ization, stringency washing with PR-1006 was at 53 °C, and with PR-
1005 at 52 °C.
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plete cosegregation of heterozygosity for the l,691G -» A muta-
tion with APC resistance (n-APC-SR<0.84) äs shown for pari
of the pedigree (Fig. 4α). Four patients (II.6, II.8, 11.14, 111.22),
for whom no n-APC-SR could be determined because of oral
anticoagulant treatment, were found to be heterozygous.
In a previous study of 301 consecutive patients who had suf-
fered a first episode of deep vein thrombosis and of 301 age-
and sex-matched controls from the general population, 64 APC-
resistant thrombosis patients had been identified5. These 64
patients and their 64 controls were screened for the presence
of the G->A Substitution. Seventy had n-APC-SRC <0.84 (64
patients, 6 controls), of which 56 carried the mutation (53
patients, 3 controls), in both alleles in six of the patients (mean
n-APC-SR, 0.43; ränge, 0.41-0.44) and in one allele in 50
patients (mean n-APC-SR, 0.57; ränge, 0.50-0.67). The remain-
ing 14 APC-resistant mdividuals did not carry the mutation and
had only a marginally reduced n-APC-SR (mean n-APC-SR,
0.78; ränge, 0.70-0.83). None of the 58 individuals who were
not APC-resistant carried the mutation (mean n-APC-SR, 0.99;
ränge, 0.83-1.19). Further, none of 100 consecutive thrombosis
patients with n-APC-SR > 0.84 was a carrier of the mutation,
whereas 3 of their 100 matched controls were, äs expected. These
three (n-APC-SR values 0.57, 0.58 and 0.59) were the only con-
trols with n-APC-SR < 0.84.
Our results show that 80% of the individuals with n-APC-
SR < 0.84 and 100% ofthose with n-APC-SR < 0.70 are hetero-
zygotes or homozygotes for the mutation and that all carriers
of the mutation have n-APC-SR < 0.7. The high frequency of
the mutated allele in the Dutch population (about 2%) combined
with our previous finding5 that APC resistance is a common and
strong risk factor for deep vein thrombosis, makes this heredit-
ary factor V defect the most common hereditary blood coagula-
tion disorder identified so far. A founder effect may be involved
in the spread of this disorder in the population, äs suggested by
the overrepresentation of the common Hmfl allele of the factor
V gene (cytosine at nucleotide 2,298; Fig. 2 legend) in carriers
of the factor V Leiden mutation; the frequency of 2,298C was
0.96 in 53 carriers of the mutation and 0.73 in 69 non-carriers
(*d,fr= 30.4, d.f. = l ;P< 0.001). D
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